Abstract:
Studies in animal models of type 2 diabetes have shown that glucagon-like peptide-1 (GLP-1) receptor agonists prevent β-cell loss. Whether GLP-1 mediates β-cell survival via the key lysosomal-mediated process of autophagy is unknown.
Here we report that treatment of INS-1E β-cells and primary islets with glucolipotoxicity (0.5mmol/l palmitate, 25mmol/l glucose) increases LC3 II, a marker of autophagy. Further analysis indicates a blockage in autophagic flux associated with lysosomal dysfunction. Collectively, our data highlights lysosomal dysfunction as a critical mediator of β-cell loss and shows that exendin-4 improves cell survival via restoration of lysosomal function and autophagic flux. Modulation of autophagy / lysosomal homeostasis may thus define a novel therapeutic strategy for type 2 diabetes, with the GLP-1 signalling pathway as a potential focus.
Macroautophagy (hereafter referred to as autophagy) is the principle lysosomal mediated mechanism for the degradation of misfolded proteins and damaged organelles to sustain intracellular homeostasis and core metabolic functions (1) . Cytosolic components are engulfed by autophagosomes which fuse with lysosomes to allow for degradation of contents by lysosomal hydrolases. This process generates amino acids, lipids and nucleotides for biosynthesis or for use as energy sources during starvation and can also serve to remove superfluous nutrients in metabolically active tissues. Under most conditions, autophagy acts to prevent or delay cell death, but can result in cell death through deregulation or exacerbation. Lysosomal function and fusion with autophagosomes are critical mediators of autophagic flux and its pro-survival vs. pro-death role (1) (2) (3) .
Recent studies have implicated a role for β-cell autophagy in the development of type 2 diabetes (4). The overt β-cell failure evident in type 2 diabetes (5) is a consequence of both deterioration of function and loss of cell mass (6) and is in part attributed to the cytotoxic effects of chronically elevated glucose and fatty acids (glucolipotoxicity) (7) . The impact of gluco-/lipo-toxicity on β-cell autophagy has been proposed to be both beneficial and detrimental to cell survival. Autophagy-deficient β-cells show compromised function and survival upon high-fat feeding supporting a protective role for autophagy (8) , a finding supported by in vitro studies of gluco-/lipo-toxicity (9-13. In contrast, other studies report that chronic lipotoxicity causes defective autophagic turnover leading to cell death (14) (15) (16) , consistent with increased autophagosome accumulation in human and rodent type 2 diabetes (17) (18) . Such studies have suggested that the impairment in autophagic flux may be secondary to defects in lysosomal function (14, 16) but the underlying mechanisms have not been elucidated and the impact of this defect on lysosomal-mediated cell death has not been explored.
Glucagon Like Peptide-1 (GLP-1) receptor agonists lower blood glucose through distinct actions on various organs including β-cells (19) . GLP-1 agonists enhance insulin secretory capacity by increasing glucose-induced insulin secretion and by preserving β-cell mass by stimulation of β-cell proliferation and inhibition of cell death (20) . Studies in other tissues, including liver and spinal cord, have shown that GLP-1 agonists activate autophagy and that this mechanism is essential for the cell survival effects of the drug (21, 22) . However, the precise role of GLP-1 in regulating β-cell autophagy and its impact on cell fate has not been defined. To this aim we have explored the role for autophagy in the pro-survival effects of GLP-1 in β-cells exposed to glucolipotoxicity. The results provide a mechanistic insight into the deregulation of autophagy and lysosomal dysfunction in pancreatic β-cells exposed to excess nutrients and identify restoration of these pathways as critical components for the prosurvival effect of the GLP-1 receptor agonist exendin-4.
Research Design and Methods

Rodent Islet isolation
8-10 week old C57BL/6 mice fed ad libitum were euthanised by cervical dislocation. All procedures conformed to Home Office Regulations and approved by Newcastle University Ethical Committee. Pancreases were perfused with collagenase-P via the common bile duct and islets purified using a Histopaque gradient (23) with a final filtration step using a 70 µm filter. Islets were cultured overnight in RPMI-1640 supplemented with 10% FBS and 50 U/ml penicillin and 50 μg/ml streptomycin prior to treatment.
Human Islets
Human islets were isolated from 7 non-diabetic donors at the Clinical Islet Lab, University of Alberta, Canada or the Islet Isolation Unit, Kings College London, UK with appropriate ethical approval. Islets were transported to Newcastle and maintained in CMRL media supplemented with 0.5% human albumin serum and 50 U/ml penicillin and 50 μg/ml streptomycin for 24 h prior to treatment. were studied. Ethical approval was acquired from Newcastle and North Tyneside ethics committee and research consent obtained. Following fixation in formalin and embedding in paraffin, indirect immunofluorescence staining was carried out as in (24) . Tissue was imaged using a Zeiss Axio Imager II microscope and a minimum of five islets from one section was imaged per patient. The p62 signal intensity of the islets was quantified using ImageJ and non-islet staining subtracted. Data is expressed as p62 intensity/islet.
Immunohistochemical analysis of human tissue
Cell culture
INS-1E cells were cultured in RPMI-1640 media containing 50 μmol/l β-mercaptoethanol, 1 mmol/l sodium pyruvate, 50 U/ml penicillin, 50 μg/ml streptomycin and 5% FBS.
Palmitate:BSA was prepared as in (11) . For Atg5 silencing, INS-1E cells were transfected with scrambled siRNA or siRNA targeted against Atg5 for 48 h using Lipofectamine® RNAiMAX (Thermo Fisher, Loughborough, UK) according to the manufacturer's instructions.
INS-1E(mCherry-GFP-LC3) model
INS-1E cells were transfected with pBABE-puro mCherry-EGFP-LC3B (a gift from Jayanta Debnath (25) (Addgene plasmid # 22418)) and cells selected using 1 µg/ml puromycin. INS-1E (mCherry-GFP-LC3) cells were plated on chambered coverslips and nuclei stained with 4.5 µg/ml Hoechst for 5 min. Live cell imaging was performed in a heated environmental chamber (37°C, 5% CO2) using either a Nikon TE2000 (×100) or using a Nikon AIR (x100).
Images were processed using NIS Element Imaging software and puncta quantified using Volocity.
INS-1E(GFP-LC3) model
INS-1E cells were transfected with EGFP-LC3 (26) (a gift from Karla Kirkegaard (Addgene plasmid #11546)) and cells selected using 1 µg/ml puromycin. INS-1E(GFP-LC3) were plated onto coverslips and co-stained with 75 nmol/l lysotracker Red DND-99 (ThermoFisher) for 30 min before fixation with 4% paraformaldehyde. Nuclei were stained with 4.5 µg/ml Hoechst 33342 and coverslips mounted onto slides. Cells were imaged using a Nikon Eclipse E400 (x60). Co-localisation between GFP-LC3 and lysosomes was visually quantified as the number of GFP-LC3 puncta co-staining for lysotracker. This analysis was performed by two independent observers, one unaware of sample identity.
Cell death measurements
For PI/Hoechst staining, INS-1E / human islets cells were incubated with 10 µg/ml propidium iodide and 10 µg/ml Hoechst-33342 for 20 min. Images were taken with a Nikon TE2000 (×20). For INS-1E, >1000 cells were counted per condition and analysis performed using ImageJ software. For human islets, a minimum of ten islets were analysed and % viability estimated visually by two independent observers, one unaware of sample identity.
Apoptosis was determined using the Caspase-Glo® 3/7 Assay (Promega, Southampton, UK)
or by western blotting for cleaved caspase 3.
Western blotting
Proteins were fractionated using 4-12% SDS/PAGE gels (Bio-rad, Hertfordshire, UK) and transferred to PVDF. Membranes were probed with primary antibody (Table S1 ) at 4°C
overnight. After incubation with secondary antibody conjugated to horseradish peroxidase, bands were detected using enhanced chemiluminescence. Immunoblots were quantified using ImageJ.
Immunostaining
Cells plated onto coverslips were fixed with 4% paraformaldehyde and immunostaining performed as in (27) . Cells were imaged using a Nikon TE2000 (×100). Lysosomal puncta were quantified using Blobfinder software (Uppsala University, Sweden). TFEB translocation was quantified by measurement of the mean pixel intensity for the nuclear and cytoplasmic compartments using ImageJ and the nuclear:cytoplasmic ratio calculated.
Cathepsin activity assays
For cathepsin activity, INS-1E plated in 24-well plates were extracted into 200 µl cell lysis buffer and Cathepsin B / D detected according to the manufacturer's instructions (Merck Millipore (CBA001) and RayBiotech, Norcross, USA (68AT-CathD-S100), respectively).
RNA extraction and RT-PCR
RNA was extracted using TRIzol (Thermo Fisher) and cDNA was synthesized from 1 g of RNA with MMLV (Promega). Real-time RT-PCR was performed as in (28) using custom designed primers (Table S1 ). Relative mRNA levels were calculated by delta cycle threshold, corrected for cyclophilin A and are expressed relative to control.
Subcellular Fractionation
For analysis of TFEB translocation, nuclear and cytosolic extracts were prepared as in (29) .
For analysis of lysosomal membrane permeabilisation, cytosolic extracts were prepared as in (30) .
Statistics
Results are expressed as means ± SEM for the number of cell preparations and values compared using either the Student's t-test (paired or unpaired) or by one or two-way ANOVA followed by Bonferroni's test.
Results
Exendin-4 increases autophagic flux in β-cells exposed to glucolipotoxicity
We first confirmed the protective effects of the GLP-1 agonist exendin-4 over β-cell death.
Treatment of INS-1E with glucolipotoxicity (25 mmol/l glucose and 0.5 mmol/l palmitate, (GLT)) increased cell death ( Figure 1A ) and apoptosis ( Figure 1B ), which were partially prevented by co-treatment with 100 nmol/l exendin-4 ( Figure 1A and B). GLT also increased cell death and apoptosis in human islets and exendin-4 partially prevented this ( Figure 1C -E).
GLT increased basal autophagic activity, as evidenced by increased LC3 II in INS-1E and in mouse and human islets ( Figure 1F -H). Exendin-4 had no effect in the absence of GLT but exacerbated the GLT-induced increase in LC3 II ( Figure 1F -H).
To investigate autophagic flux, we evaluated LC3 II in the presence of the lysosomal inhibitor chloroquine (31) . As expected, chloroquine increased LC3 II ( Figure 2A ). GLT continued to increase LC3 II in the presence of chloroquine suggesting autophagic stimulation. However, the effect of GLT was greater in the absence of chloroquine than in its presence (GLT w/o chloroquine 4.8-fold -/+ 0.23 increase, vs. GLT + chloroquine 2.2-fold -/+ 0.46 increase in LC3II/GAPDH, p<0.005), suggesting partial blockage of autophagic flux.
To further explore this, we used two more robust methods to assess autophagic flux, mCherry-GFP-LC3 analysis and p62 accumulation (31) . We first generated INS-1E stably expressing mCherry-GFP-LC3 ( 
Autophagy contributes to the pro-survival effects of Exendin-4
To determine whether autophagy contributes to the pro-survival effects of exendin-4, we first explored the impact of impaired autophagic flux on cell survival. Live-cell imaging of INS-1E(mCherry-GFP-LC3) treated with GLT showed that cells with apparent autophagic dysfunction as evident by large yellow puncta (at 4-6 h), showed evidence of cell death (cell rounding, detachment, loss of fluorescence) at later time-points (indicated by arrows in Figure 3A , Video S1). Further assessment using siRNA knockdown of the key autophagic gene Atg5 showed that silencing of Atg5 ( Figure 3B ) partially prevented the exendin-4 induced increase in LC3 II ( Figure 3B , C). Silencing of autophagy did not prevent the GLTinduced increase in cell death but did reverse the protective effect of exendin-4, as evidenced by the increase in PI staining ( Figure 3D ). The impact of exendin-4 on autophagy is therefore essential for its protective role on β-cell survival.
Exendin-4 prevents the glucolipotoxicity-induced impairment in lysosomal function
The mechanism/s for the impairment in autophagic flux in response to GLT are not well understood although a role for lysosomal dysfunction has been proposed (14, 16) . To understand how exendin-4 prevents the deregulation of autophagic flux, lysosomal function was assessed. Treatment of INS-1E with GLT decreased lysosomal staining as determined using lysotracker dye and immunostaining for Lamp2, which was partially prevented by cotreatment with exendin-4 ( Figure 4A and B). GLT also decreased cathepsin B activity and exendin-4 reversed this ( Figure 4C ). These effects were not due to changes in protein expression ( Figure S1A 
Glucolipotoxicity stimulates lysosomal biogenesis via TFEB translocation
To determine whether the changes in lysosomal function could be explained by alterations in lysosomal biogenesis, we investigated the regulation of transcription factor EB (TFEB).
TFEB upregulates expression of genes involved in lysosomal biogenesis and function, autophagosome biogenesis and autophagosome-lysosome fusion (33) (34) . 
Glucolipotoxicity induces cell death via lysosomal membrane permeabilisation
The accumulation of defective lysosomes with their high concentration of hydrolytic enzymes is potentially hazardous for the cell. Release of these components into the cytoplasm via lysosomal membrane permeabilisation (LMP) can initiate cell death (35) . To determine whether the accumulation of defective lysosomes directly contributes to β-cell death, LMP was investigated. Staining of INS-1E for cathepsin B and D showed loss of punctate staining following treatment with GLT, which was prevented by co-treatment with exendin-4 ( Figure   6A and B). Such a staining pattern in the absence of changes in protein expression ( Figure   S1B and C) can be indicative of LMP. Further assessment by isolation of cytoplasmic fractions showed that exposure to GLT caused release of cathepsin D into the cytoplasm, which was prevented by co-treatment with exendin-4 ( Figure 6C ). The impact of LMP on total cell death was assessed using cathepsin inhibitors. Co-treatment with antipain, a nonspecific inhibitor, partially prevented the GLT-induced increase in β-cell death ( Figure 6D ).
Further analysis using specific inhibitors of cathepsin B (CBi, CA-074) and cathepsin D (CDi, PepstatinA) ( Figure S1D and E) showed that whilst CBi had no effect ( Figure 6E 
Defect in lysosomal function is downstream of ER stress
To elucidate the mechanisms underlying GLT-induced lysosomal dysfunction and its reversal by exendin-4, we investigated whether the lysosomal dysfunction was dependent on autophagy. Autophagy was chemically modulated using 3-methyladenine (3-MA). Despite inhibition of LC3 II formation in response to GLT ( Figure 7A) , there was no effect of 3-MA on the GLT-dependent decrease in lysosomal staining or its reversal by exendin-4 ( Figure   7B ), suggesting that these changes are independent of autophagy.
Endoplasmic reticulum (ER) stress is a major driver in GLT-induced cell death (36) . To determine whether ER stress also plays a role in GLT-induced lysosomal dysfunction, ER stress was assessed. GLT increased ER stress as evident by an increase in p-eIF2a and CHOP
( Figures 7C and D) . Blockage of ER stress with the inhibitor tauroursodeoxycholic acid (TUDCA) (Figure 7E ), partially prevented the increase in LC3 II induced by GLT ( Figure 7F ) and also prevented the decrease in lysosomal staining ( Figure 7G ), and the GLTinduced increase in cell death ( Figure 7H ). This data supports a model by which ER stress stimulates autophagy but also impairs lysosomal function, preventing fusion of lysosomes with autophagosomes leading to blockage of autophagic flux. Consistent with previous studies (37) (38) , the GLT-induced increase in ER stress was attenuated by co-incubation with exendin-4 ( Figure 7I ). This attenuation of ER stress by exendin-4 may underlie the improvement in lysosomal function.
JNK mediates glucolipotoxicity-induced autophagy but not lysosomal dysfunction
We next sought to elucidate the signalling pathways linking ER stress with autophagy and lysosomal dysfunction. Previous studies have linked ER stress to autophagy via JNK signalling (39) but whether JNK regulates lysosomal function is unknown.
GLT increased JNK phosphorylation ( Figure 7J ). Inhibition of JNK-P using SP600125
prevented the GLT-induced increase in LC3 II ( Figure 7J and K), but not GLT-induced decrease in lysosomal staining ( Figure 7L ). This data shows that whilst JNK signalling mediates the downstream ER stress mechanisms linking to autophagy, it does not mediate the lysosomal dysfunction induced by GLT. There was no effect of exendin-4 on JNK Whether the regulation of β-cell autophagy by gluco-/ lipo-toxicity represents a pro-survival or pro-death mechanism is contentious (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Some studies support a protective role for autophagy in regulating β-cell mass in response to excess nutrients (8-13), whilst others suggest that these stimuli impair autophagic flux leading to cell death (14) (15) (16) (17) (18) . Our data shows that GLT stimulates β-cell autophagy but that it also impairs flux through the induction of lysosomal dysfunction as indicated by decreased lysosomal staining and decreased cathepsin activity, consistent with previous models of β-cell lipotoxicity (14, 16 ).
This does not appear to be due to an impairment in lysosomal biogenesis, since GLT causes nuclear translocation of TFEB and upregulation of downstream gene transcription. The enlarged lysosomal vesicles are distinct from the accumulated autophagosomes as evident from the loss of overlap between lysosomal stains and autophagosomal GFP-LC3, indicating loss of lysosomal-autophagosomal fusion at later time points. Chemical inhibition of autophagy and ER stress show that the defect in lysosomal dysfunction is independent from autophagy but downstream of the GLT-induced increase in ER stress. ER stress also appears to be a major driver in the increase in autophagic signalling, consistent with a previous study (39) . However, further analysis indicate differing downstream pathways regulating autophagy and lysosomal dysfunction, JNK dependent and independent, respectively. These findings support a model whereby GLT induces ER stress which both stimulates autophagy and induces lysosomal dysfunction. We predict that the increased activation of autophagy in the presence of impaired lysosomal fusion leads to deregulation of autophagic flux and accumulation of autophagosomal and lysosomal vesicles (Figure 8 ).
The accumulation of autophagic vesicles in tissue from type 2 diabetic patients by both p62 accumulation (current study and 17) and ultrastructure analysis (18) , suggests that the impairment in autophagic flux may contribute to the loss of β-cell mass in type 2 diabetes.
This hypothesis is supported by our mCherry-GFP-LC3 data showing that following exposure to GLT, cells with impaired autophagic flux appear to undergo cell death at later time points, unlike cells with normal flux which are more likely to survive. Furthermore, the improvement in β-cell survival induced by exendin-4 was dependent on restoration of autophagic signalling. This is similar to that reported for the autophagy activators rapamycin and carbamazepine, which improved β-cell survival under lipotoxic conditions (11, 13, 15) .
Studies in other cell types have shown that an impairment in autophagic flux can lead to cell death via apoptosis, non-apoptotic mechanisms and also via lysosomal-mediated cell death (35) . Alterations in lysosomal enzymes / protein expression has been reported in both human and rodent type 2 diabetes (18, 40) but their contribution to cell death has not been explored.
The current study provides strong evidence that the defect in lysosomal function contributes directly to cell death via lysosomal membrane permeabilisation (LMP) (Figure 8 (45), suggesting that the underlying mechanism of autophagic dysfunction may determine the impact of GLP-1 agonists. There was no effect of exendin-4 on autophagy in the absence of GLT, in agreement with a previous study (17) . C.A. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
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C-E.
Human islets were cultured with or without GLT / exendin-4 for 48-72 h. C. Viability was assessed using PI staining and quantified as percentage viability. D-E. Apoptosis was assessed by western blotting for cleaved caspase 3 and quantified as cleaved caspase 3 / GAPDH ratio (D) or using the Caspase-Glo 3/7 assay (E).
F-H. INS-1E (F)
, mouse (G) or human (H) islets were cultured with or without GLT / exendin-4 for either 6 h (F) or 48 h (G-H). LC3 was analysed by western blotting and quantified as LC3 II / GAPDH ratio.
N.B. Human islets consistently show higher basal LC3 II levels compared to INS-1E and mouse islets. This may be a consequence of the islet isolation procedure which places the islets under unavoidable stresses.
Results are normalised to control and expressed as fold change. Mean ± SEM of 4-6 individual experiments. *P <0.05, **P <0.01, ***P <0.005 vs. control; # P < 0.05, ## P < 0.01, ### P < 0.005 effect of exendin-4. 
D. INS-1E
were cultured on coverslips with or without GLT / exendin-4 for 16 h. Cells were fixed, immunostained for p62 and visualised using fluorescence microscopy. p62 puncta were quantified using Blobfinder software and expressed as number of p62 puncta / cell.
E.
Representative immunohistochemical staining of p62 (red) and Insulin (green) from nondiabetic patients and patients with T2DM. Nuclei are stained with Hoechst (blue). Tissue was visualised using confocal microscopy. Images are representative of 3 patients with T2D and 5
controls. The intensity of islet p62 staining was quantified in control and T2D tissue, and is expressed as p62 intensity/islet.
Mean ± SEM of 3-6 individual experiments. *P < 0.05, **P <0.01, ***P <0.005 vs. control; # P < 0.05 effect of exendin-4; ^ P < 0.05, ^^ P < 0.01, ^^^ P < 0.005 effect of chloroquine.
Image scale bars represent 10 µm. 
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